Benzodiazepines for anxiety disorders: Maximising the benefits and minimising the risks

Advances in Psychiatric Treatment

Volumn 18, Issue 4, 2012, Pages 250-258

  Starcevic, Vladan ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEPEAN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHYL LOFLAZEPATE; LORAZEPAM; OXAZEPAM;

ALCOHOL CONSUMPTION; AMNESIA; ANXIETY DISORDER; COGNITIVE DEFECT; DEPRESSION; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG SEEKING BEHAVIOR; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEAR; GABAERGIC TRANSMISSION; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT SELECTION; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PSYCHIATRIC TREATMENT; PSYCHOMOTOR DISORDER; RELAPSE; REVIEW; SLEEP; WITHDRAWAL SYNDROME;

EID: 84864399154     PISSN: 13555146     EISSN: 14721481     Source Type: Journal    
DOI: 10.1192/apt.bp.110.008631     Document Type: Review

References (45)

1. Andersch S, Hetta J (2003) A 15-year follow-up study of patients with panic disorder. European Psychiatry 18: 401-8.
2. Balter MB, Levine J, Manheimer D (1974) Cross-national study of the extent of anti-anxiety/sedative drug use. New England Journal of Medicine 290: 769-74.
3. Barbone F, McMahon AD, Davey PG, et al (1998) Association of roadtraffic accidents with benzodiazepine use. Lancet 352: 1331-6.
4. Barker MJ, Greenwood KM, Jackson M, et al (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18: 37-48.
5. Biondi M, Picardi A (2003) Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioural therapy: a follow-up study. Psychotherapy and Psychosomatics 72: 34-42.
6. Bruce SE, Vasile RG, Goisman RM, et al (2003) Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? American Journal of Psychiatry 160: 1432-8.
7. Busto UE, Bremner KE, Knight K, et al (2000) Long-term benzodiazepine therapy does not result in brain abnormalities. Journal of Clinical Psychopharmacology 20: 2-6.
8. Cowley DS, Ha EH, Roy-Byrne PP (1997) Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry 58: 555-61.
9. Cross-National Collaborative Panic Study, Second Phase Investigators (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. British Journal of Psychiatry 160: 191-202.
10. Davidson JRT, Petts N, Richichi E, et al (1993) Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 13: 423-8.
11. Deckersbach T, Moshier SJ, Tuschen-Caffier B, et al (2011) Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. Depression and Anxiety 28: 999-1007.
12. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al (2008) Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). Journal of Affective Disorders 110: 84-93.
13. Freeman SA (2009) The benzodiazepine stigma persists. Journal of Clinical Psychiatry 70: 1727-8.
14. Gelernter CS, Uhde TW, Cimbolic P, et al (1991) Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry 48: 938-45.
15. Goddard AW, Brouette T, Almai A, et al (2001) Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 58: 681-6.
16. Haefely W (1986) Biological basis of drug-induced tolerance, rebound, and dependence: contribution of recent research on benzodiazepines. Pharmacopsychiatry 19: 353-61.
17. Healy D (2002) Psychiatric Drugs Explained. Third Edition: 142. Churchill Livingstone.
18. Lucki I, Rickels K, Geller AM (1986) Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berlin) 88: 426-33.
19. Mol AJJ, Gorgels WJMJ, Voshaar RCO, et al (2005) Associations of benzodiazepine craving with other clinical variables in a population of general practice patients. Comprehensive Psychiatry 46: 353-60.
20. Nagy LM, Krystal JH, Woods SW, et al (1989) Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study. Archives of General Psychiatry 46: 993-9.
21. Noyes R, Garvey MJ, Cook B (1991) Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry 148: 517-23.
22. O'Brien CP (2005) Benzodiazepine use, abuse, and dependence. Journal of Clinical Psychiatry 66 (suppl 2): 28-33.
23. Otto MW, Pollack MH, Sachs GS, et al (1993) Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. American Journal of Psychiatry 150: 1485-90.
24. Pollack MH, Otto MW, Tesar GE, et al (1993) Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. Journal of Clinical Psychopharmacology 13: 257-63.
25. Pollack MH, Simon NM, Worthington JJ, et al (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. Journal of Psychopharmacology 17 : 276-82.
26. Pradel V, Delga C, Rouby F, et al (2010) Assessment of abuse potential of benzodiazepines from a prescription database using "doctor shopping" as an indicator. CNS Drugs 24: 611-20.
27. Rapoport MJ, Lanctot KL, Streiner DL, et al (2009) Benzodiazepine use and driving: a meta-analysis. Journal of Clinical Psychiatry 70: 663-73.
28. Rickels K, Downing R, Schweizer E, et al (1993) Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50: 884-95.
29. Rickels K, DeMartinis N, Aufdembrinke B (2000) A double-blind, placebocontrolled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 20: 12-8.
30. Rosenbaum JF, Moroz G, Bowden CL (1997) Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Journal of Clinical Psychopharmacology 17: 390-400.
31. Rosenbaum JF (2005) Attitudes toward benzodiazepines over the years. Journal of Clinical Psychiatry 66 (suppl 2): 4-8.
32. Rothschild AJ, Shindul-Rothschild J, Viguera A, et al (2000) Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. Journal of Clinical Psychopharmacology 20: 7-11.
33. Salzman C (1991) The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. American Journal of Psychiatry 148: 151-2.
34. Salzman C, Miyawaki EK, le Bars P, et al (1993) Neurobiologic basis of anxiety and its treatment. Harvard Review of Psychiatry 1: 197-206.
35. Schweizer E, Rickels K, Weiss S, et al (1993) Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry 50: 51-60.
36. Shader RI, Greenblatt DJ (1993) Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 328: 1398-405.
37. Smolders M, Laurant M, van Rijswijk E, et al (2007) The impact of comorbidity on GPs' pharmacological treatment decisions for patients with an anxiety disorder. Family Practice 24: 538-46.
38. Soumerai SB, Simoni-Wastila L, Singer C, et al (2003) Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatric Services 54: 1006-11.
39. Spiegel DA, Bruce TJ, Gregg SF, et al (1994) Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? American Journal of Psychiatry 151: 876-81.
40. Stahl SM (2002) Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. Journal of Clinical Psychiatry 63: 756-7.
41. Starcevic V (2011) Have anxiety disorders been disowned by psychiatrists? Australasian Psychiatry 19: 12-6.
42. Uhlenhuth EH, Balter MB, Ban TA, et al (1999) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. Journal of Clinical Psychopharmacology 19 (suppl 2): 23-29S.
43. Vasile RG, Bruce SE, Goisman RM, et al (2005) Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depression and Anxiety 22: 59-67.
44. Wagner AK, Ross-Degnan D, Gurwitz JH, et al (2007) Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Annals of Internal Medicine 146: 96-103.
45. Worthington JJ, Pollack MH, Otto MW, et al (1998) Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacology Bulletin 34: 199-205.